IP Library › Granted Patent US 12,241,053
Granted Patent B2
US 12,241,053 · App. 15/767,074 · Granted Mar 4, 2025

Modulation of novel immune checkpoint targets

Inventors: Vijay K. Kuchroo (Boston, MA); Ana C. Anderson (Boston, MA); Asaf Madi (Boston, MA); Norio Chihara (Boston, MA); Aviv Regev (Cambridge, MA); Meromit Singer (Cambridge, MA)
Assignees: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.; THE BROAD INSTITUTE, INC.; MASSACHUSETTS INSTITUTE OF TECHNOLOGY
C07K14/705A61K39/39A61K39/4611A61K39/464492A61P31/04A61P31/12A61P35/00C12N5/0636C12N15/62C12Q1/6827C12Q1/686C12Q1/6881A61K2239/31A61K2239/57C12N2501/2327C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,241,053
App. No.
15/767,074
Granted
Mar 4, 2025
Kind
B2
Abstract

Dysfunctional or exhausted T cells arise in chronic diseases including chronic viral infections and cancer, and express high levels of co-inhibitory receptors. Therapeutic blockade of these receptors has clinical efficacy in the treatment of cancer. While co-inhibitory receptors are co-expressed, the triggers that induce them and the transcriptional regulators that drive their co-expression have not been identified. The immunoregulatory cytokine IL-27 induces a gene module in T cells that includes several known co-inhibitory receptors (Tim-3, Lag-3, and TIGIT). The present invention provides a novel immunoregulatory network as well as novel cell surface molecules that have an inhibitory function in the tumor microenvironment. The present invention further provides the novel discovery that the transcription factors Prdm1 and c-Maf cooperatively regulate the expression of the co-inhibitory receptor module. This critical molecular circuit underlies the co-expression of co-inhibitory receptors in dysfunctional T cells and identifies novel regulators of T cell dysfunction.

Claims (22)

1. An isolated immune cell genetically modified to (a) downregulate or abolish expression or activity of a gene encoding protein C receptor (PROCR) and one or more genes selected from the group consisting of genes encoding PRDMI, c-MAF, and Podoplanin (PDPN); or (b) comprise an agent capable of inducibly downregulating expression or activity of a gene encoding PROCR and one or more genes encoding PRDMI, c-MAF, and PDPN.

2. The isolated immune cell according to claim 1 , wherein the isolated immune cell is a CD8+ T cell that displays tumor specificity.

3. The isolated immune cell according to claim 1 , wherein the PROCR gene, and one or more of the PRDMI, c-MAF, or PDPN genes are genetically modified using a protein comprising

(i) a DNA-binding portion configured to specifically bind to the PROCR gene, and one or more of the PRDMI, c-MAF, or PDPN genes and (ii) a DNA cleavage portion that comprises:

a zinc finger protein or DNA-binding domain thereof, a transcription activator-like effector (TALE) protein or DNA-binding domain thereof, or an RNA-guided protein or DNA-binding domain thereof;

a Cas protein modified to eliminate its nuclease activity; or

a DNA-binding domain of a Cas protein;

wherein the protein is a nuclease or a heterologous repressor protein capable of repressing the transcription of the PROCR, PRDM1, c-MAF, or PDPN genes.

4. The isolated immune cell according to claim 1 , wherein the isolated immune cell is genetically modified to downregulate or abolish expression or activity of genes encoding PDPN, PRDM1, c-MAF, and PROCR.

5. A cell population of immune cells as defined in claim 1 .

6. A method for generating the isolated immune cell as defined in claim 1 , the method comprising (i) providing an isolated immune cell, and (ii) genetically modifying said isolated immune cell to comprise an altered expression or activity of a gene encoding PROCR and genes encoding one or more of PDPN, PRDMI and c-MAF.

7. A pharmaceutical composition comprising the isolated immune cell according to claim 1 .

8. The isolated immune cell according to claim 1 , wherein the isolated immune cell is further genetically modified to alter expression or activity of one or more genes encoding PD1, CTLA4, TIGIT, TIM3, LAG3, and PDL1.

9. The isolated immune cell according to claim 1 , wherein the isolated immune cell is further genetically modified to alter expression or activity of one or more genes encoding TIGIT, LAG3, LILRB4, and KLRC1.

10. The isolated immune cell according to claim 1 , wherein the isolated immune cell is further genetically modified to alter expression or activity of one or more genes encoding CD226, OX-40, GITR, TNFSF9 (4-1BB), KLRC2, KLRE1, KLRK1, IL12RB1, IL1R1, and SLAMF7.

11. The isolated immune cell according to claim 1 , wherein the isolated immune cell is further genetically modified to alter expression or activity of one or more genes encoding TIGIT, LAG3, LILRB4, ALCAM, and KLRC1.

12. The isolated immune cell according to claim 1 , wherein the isolated immune cell is further genetically modified to alter expression or activity of one or more genes encoding BTLA, TIGIT, HAVCR2 (TIM-3), LAG3, IL10RA, IL1R2, LILRB4, KLRC1, KLRC2, KLRE1, TNFSF9 (4-1BB), KLRK1, IL12RB1, IL1R1, and SLAMF7.

13. The isolated immune cell according to claim 1 , wherein the isolated immune cell is further genetically modified to comprise an agent capable of inducibly altering expression or activity of one or more genes encoding PD1, CTLA4, TIGIT, TIM3, LAG3, PDL1, LILRB4, KLRC1, CD226, OX-40, GITR, TNFSF9 (4-IBB), KLRC2, KLRE1, KLRK1, IL12RB1, IL1R1, and SLAMF7.

14. The isolated immune cell according to claim 1 , wherein the isolated immune cell is genetically modified to decrease expression or activity of genes encoding PROCR and PRDMI; genes encoding PROCR and c-MAF; or genes encoding PROCR and PDPN.

15. The isolated immune cell according to claim 1 , wherein the isolated immune cell is genetically modified to decrease expression or activity of genes encoding PROCR, PRDM1 and c-MAF; or genes encoding PROCR, PRDM1 and PDPN.

16. The isolated immune cell according to claim 1 , wherein the isolated immune cell is genetically modified to decrease expression or activity of genes encoding PROCR, c-MAF and PDPN.

17. The isolated immune cell according to claim 1 , wherein the isolated immune cell is genetically modified to decrease expression or activity of genes encoding PROCR, PRDM1, c-MAF, and PDPN.

Continuity (2)
Provisional Application 62239548 · Oct 9, 2015
Related Publication 20190255107A1 · Aug 22, 2019
References Cited (38)
WO WO2009092087A2 · 2009 [cited by applicant]
WO WO2014059173A2 · 2014 [cited by applicant]
WO WO2014070874A1 · 2014 [cited by applicant]
WO WO2014134351A2 · 2014 [cited by applicant]
WO WO2015075175A1 · 2015 [cited by examiner]
WO WO2015143343A2 · 2015 [cited by applicant]
WO WO2015174439A1 · 2015 [cited by applicant]
WO WO2016109546A2 · 2016 [cited by applicant]
Ochoa-Alvarez (2015, Oncotarget, 6(11):9045-9060). [cited by examiner]
Oft (Cancer Immunol Res; 2(3) Mar. 2014, 194-199). [cited by examiner]
Neumann (J. Exp. Med. 2014 vol. 211 No. 9 1807-1819). [cited by examiner]
Nirschi (2013, Clin Cancer Res; 19(18); 4917-24) (Year: 2013). [cited by examiner]
Anderson et al., “Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation”, Immunity, 2016, vol. 44, No. 5, pp. 989-1004. [cited by applicant]
Peters et al., “Podoplanin negatively regulates CD4 effector T-cell responses”, Journal of Clinical Investigation, 2014, vol. 125, pp. 129-140. [cited by applicant]
Sakuishi et al., “Targeting TIM-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity”, Journal of Experimental Medicine, 2010, vol. 207, pp. 2187-2194. [cited by applicant]
Singer et al., “A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T cells”, Cell, 2016, vol. 166, No. 6, p. 1500. [cited by applicant]
Tirosh et al., “Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq”, Science, 2016, vol. 352, No. 6282, pp. 189-196. [cited by applicant]
Zhu et al., “An IL-27/NFIL3 signaling axis drives Tim-3 and IL-10 expression and T cell dysfunction”, Nature Communications, 2015, vol. 6, 25 pages. [cited by applicant]
International Search Report issued in International Patent Application No. PCT/US2016/056177, mailed Aug. 8, 2017. [cited by applicant]
Awasthi, et al., “A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells”, Nature Immunology, 2007, vol. 8, No. 12, pp. 1380-1389. [cited by applicant]
Barber, et al., “Restoring function in exhausted CD8 T cells during chronic viral infection”, Nature, 2006, vol. 439, pp. 682-687. [cited by applicant]
Fitzgerald, et al., “Suppressive Effect of IL-27 on Encephalitogenic Th17 Cells and the Effector Phase of Experimental Autoimmune Encephalomyelitis”, The Journal of Immunology, 2007, vol. 179, pp. 3268-3275. [cited by applicant]
Fourcade, et al., “PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8? T Cells Induced by Melanoma Vaccines”, Cancer Research, 2014, vol. 74, pp. 1045-1055. [cited by applicant]
Hamid, et al., “Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma”, The New England Journal of Medicine, 2013, vol. 369, No. 2, pp. 134-144. [cited by applicant]
Hirahara, et al., “Interleukin-27 Priming of T Cells Controls IL-17 Production In trans via Induction of the Ligand PD-L1”, Immunity, 2012, vol. 36, pp. 1017-1030. [cited by applicant]
Hodi, et al., “Improved Survival with Ipilimumab in Patients with Metastatic Melanoma”, The New England Journal of Medicine, 2010, vol. 363, No. 8, pp. 711-723. [cited by applicant]
Johnston, et al., “The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function”, Cancer Cell, 2014, vol. 26, pp. 923-937. [cited by applicant]
Leach, et al., “Enhancement of Antitumor Immunity by CTLA-4 Blockade”, Science, 1996, vol. 271, pp. 1734-1736. [cited by applicant]
Mahoney, et al., “Combination cancer immunotherapy and new immunomodulatory targets”, Nature, 2015, vol. 14, pp. 561-584. [cited by applicant]
Pardoll. “The blockade of immune checkpoints in cancer immunotherapy”, Nature, 2012, vol. 12, pp. 252-264. [cited by applicant]
Robert, et al., “Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma”, The New England Journal of Medicine, 2011, vol. 364, No. 26, pp. 2517-2526. [cited by applicant]
Topalian, et al., “Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer”, The New England Journal of Medicine, 2012, vol. 366, No. 26, pp. 2443-2454. [cited by applicant]
Villarino, et al., “The IL-27R (WSX-1) Is Required to Suppress T Cell Hyperactivity during Infection”, Immunity, 2003, vol. 19, pp. 645-655. [cited by applicant]
Wherry, Kurachi, “Molecular and cellular insights into T cell exhaustion”, Nature, 2015, vol. 15, pp. 486-499. [cited by applicant]
Wherry. “T cell exhaustion”, Nature, 2011, vol. 12, No. 6, pp. 492-499. [cited by applicant]
Wolchok, et al., “Nivolumab plus Ipilimumab in Advanced Melanoma”, The New England Journal of Medicine, 2013, vol. 369, No. 2, pp. 122-133. [cited by applicant]
Woo, et al., “Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape”, Cancer Research, 2012, vol. 72, pp. 917-927. [cited by applicant]
Yoshida, et al., “The Immunobiology of Interleukin-27”, Annual Review of Immunology, 2015, vol. 33, pp. 417-443. [cited by applicant]